Condition
Epidermolysis Bullosa Acquisita
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06834035Phase 1Recruiting
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
NCT07011589Phase 1Not Yet Recruiting
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
NCT00004359Phase 2CompletedPrimary
Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
Showing all 3 trials